One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.
Watch this on-demand webinar – Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies – for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimised plasmid production process and supply.
The webinar, hosted by DDW and supported by Catalent, is presented by Matthias Craig, Senior Manager Product Development, Catalent.
You will learn:
- Key considerations during plasmid production including design and screening systems, processing, and analytical testing.
- Discover how to reduce batch-to-batch inconsistencies, improve plasmid purity, and enhance plasmid yield at every stage of upstream and downstream operations.
- The advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities.